The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for ...

Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo ...

Cancer cocktails pairing Moderna’s mRNA-4359 with Merck’s Keytruda and Marengo’s invikafusp alfa with Gilead Sciences’ ...

The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...

Executives insist Novartis will return to growth in the second half, but for Q1 2026, generic erosion drove a 5% drop in revenue, including a 46% nosedive for blockbuster heart failure drug Entresto.

Fresh off a major clinical win, Revolution Medicines alleges that Erasca’s pancreatic cancer drug infringes on key patent ...

Andrea is a Chicago-based freelance writer for BioSpace. After getting her start in entertainment journalism, she has spent ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.

After striking a Most Favored Nation deal with the White House in January, Johnson & Johnson will now offer Xarelto at 68% ...

Trained biostatisticians play a central role in clinical science and public health. Brown’s online master’s in biostatistics ...